SF1126: Updated Phase I data

Updated data from 33 evaluable patients in an ongoing, open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly SF1126

Read the full 199 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE